Cargando…

Vibrating Mesh Nebulisation of Pro-Antimicrobial Peptides for Use in Cystic Fibrosis

Background: There has been considerable interest in the use of antimicrobial peptides (AMPs) as antimicrobial therapeutics in many conditions including cystic fibrosis (CF). The aim of this study is to determine if the prodrugs of AMPs (pro-AMPs) can be delivered to the lung by a vibrating mesh nebu...

Descripción completa

Detalles Bibliográficos
Autores principales:	Forde, Éanna, Kelly, Graeme, Sweeney, Louise, Fitzgerald-Hughes, Deirdre, MacLoughlin, Ronan, Devocelle, Marc
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2019
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6571777/ https://www.ncbi.nlm.nih.gov/pubmed/31108949 http://dx.doi.org/10.3390/pharmaceutics11050239

Ejemplares similares

Pro-Moieties of Antimicrobial Peptide Prodrugs
por: Forde, Eanna, et al.
Publicado: (2015)

Effective nebulization of interferon-γ using a novel vibrating mesh
por: Sweeney, Louise, et al.
Publicado: (2019)

Nebulised lipid–polymer hybrid nanoparticles for the delivery of a therapeutic anti-inflammatory microRNA to bronchial epithelial cells
por: Vencken, Sebastian, et al.
Publicado: (2019)

Investigation of the Quantity of Exhaled Aerosols Released into the Environment during Nebulisation
por: McGrath, James A., et al.
Publicado: (2019)

Nebuliser hygiene in cystic fibrosis: evidence-based recommendations
por: Bell, Jane, et al.
Publicado: (2020)

Nebuliser Type Influences Both Patient-Derived Bioaerosol Emissions and Ventilation Parameters during Mechanical Ventilation
por: Joyce, Mary, et al.
Publicado: (2021)

Evaluation of Aerosol Therapy during the Escalation of Care in a Model of Adult Cystic Fibrosis
por: Fernández Fernández, Elena, et al.
Publicado: (2021)

Differential Performance and Lung Deposition of Levofloxacin with Different Nebulisers Used in Cystic Fibrosis
por: Schwarz, Carsten, et al.
Publicado: (2022)

Development of an intervention to increase adherence to nebuliser treatment in adults with cystic fibrosis: CFHealthHub
por: Arden, M. A., et al.
Publicado: (2021)

Single-arm, open-labelled, safety and tolerability of intrabronchial and nebulised bacteriophage treatment in children with cystic fibrosis and Pseudomonas aeruginosa
por: Singh, Jagdev, et al.
Publicado: (2023)

In Vitro Study of the Effect of Breathing Pattern on Aerosol Delivery During High-Flow Nasal Therapy
por: Bennett, Gavin, et al.
Publicado: (2019)

In Vitro Determination of the Main Effects in the Design of High-Flow Nasal Therapy Systems with Respect to Aerosol Performance
por: Bennett, Gavin, et al.
Publicado: (2018)

Case Report: Dual nebulised antibiotics among adults with cystic fibrosis and chronic Pseudomonas infection
por: Mann, Nina, et al.
Publicado: (2018)

Biopolymer-Based Nanoparticles for Cystic Fibrosis Lung Gene Therapy Studies
por: Fernández Fernández, Elena, et al.
Publicado: (2018)

Objective Nebuliser Adherence Data as “Proof” of Adherence in the Management of Cystic Fibrosis: A Qualitative Interview Study
por: Lumley, Elizabeth, et al.
Publicado: (2022)

Nebulised mesenchymal stem cell derived extracellular vesicles ameliorate E. coli induced pneumonia in a rodent model
por: Gonzalez, Hector, et al.
Publicado: (2023)

Investigating the Temporal Relationships between Symptoms and Nebuliser Adherence in People with Cystic Fibrosis: A Series of N-of-1 Observations
por: Martin, Rosie, et al.
Publicado: (2020)

P121 The effect of training about nebuliser cleaning and disinfection on the knowledge levels and practises of the caregivers of patients with cystic fibrosis
por: Cenk, M., et al.
Publicado: (2021)

Advancing mesenchymal stem cell therapy for asthma towards clinical translation
por: MacLoughlin, Ronan
Publicado: (2022)

Emulated trial investigating effects of multiple treatments: estimating combined effects of mucoactive nebulisers in cystic fibrosis using registry data
por: Granger, Emily, et al.
Publicado: (2023)

Zanamivir should be inhaled, not nebulised
por: Eagel, Barry A
Publicado: (2010)

Double Nebulisation for Airway Anaesthesia
por: Chugh, Vanya, et al.
Publicado: (2020)

Defining a Regulatory Strategy for ATMP/Aerosol Delivery Device Combinations in the Treatment of Respiratory Disease
por: Woods, Niamh, et al.
Publicado: (2020)

State of the Art Review of Cell Therapy in the Treatment of Lung Disease, and the Potential for Aerosol Delivery
por: Brave, Hosanna, et al.
Publicado: (2020)

Understanding patient activation and adherence to nebuliser treatment in adults with cystic fibrosis: responses to the UK version of PAM-13 and a think aloud study
por: Gao, Jie, et al.
Publicado: (2019)

P141 Has the COVID-19 pandemic affected medication adherence to inhaled nebulised therapy for patients at a large adult cystic fibrosis centre?
por: Iqbal, N., et al.
Publicado: (2021)

P409 Monitoring adherence to nebulised therapies during the first UK lockdown and school closure period of the COVID-19 pandemic in children with cystic fibrosis
por: Smith, C., et al.
Publicado: (2023)

The effect of UV-protected ethylene vinyl acetate (EVA) bags on the physicochemical stability of pediatric parenteral nutrition admixtures
por: Watrobska-Swietlikowska, Dorota, et al.
Publicado: (2019)

Delivered dose with jet and mesh nebulisers during spontaneous breathing, noninvasive ventilation and mechanical ventilation using adult lung models
por: Ari, Arzu, et al.
Publicado: (2021)

Repeated nebulisation of non-viral CFTR gene therapy in patients with cystic fibrosis: a randomised, double-blind, placebo-controlled, phase 2b trial
por: Alton, Eric W F W, et al.
Publicado: (2015)

The use of an alternate side lying positioning strategy during inhalation therapy does not prolong nebulisation time in adults with Cystic Fibrosis: a randomised crossover trial
por: Dentice, Ruth L., et al.
Publicado: (2018)

Side lying during nebulisation can significantly improve apical deposition in healthy adults and adults with mild cystic fibrosis lung disease: a randomised crossover trial
por: Dentice, Ruth L., et al.
Publicado: (2019)

Evaluation of polymer choice on immunogenicity of chitosan coated PLGA NPs with surface-adsorbed pneumococcal protein antigen PspA4Pro
por: Kaneko, Kan, et al.
Publicado: (2021)

Nebulisers as a potential source of airborne virus
por: Tang, Julian W., et al.
Publicado: (2020)

Cellular Immunotherapy and the Lung
por: Daly, Sorcha, et al.
Publicado: (2021)

Specialized Pro-Resolving Lipid Mediators in Cystic Fibrosis
por: Philippe, Réginald, et al.
Publicado: (2018)

Abnormal pro-gly-pro pathway and airway neutrophilia in pediatric cystic fibrosis
por: Turnbull, Andrew R., et al.
Publicado: (2020)

Exploring the impact of elexacaftor-tezacaftor-ivacaftor treatment on opinions regarding airway clearance techniques and nebulisers: TEMPO a qualitative study in children with cystic fibrosis, their families and healthcare professionals
por: Almulhem, Maryam, et al.
Publicado: (2022)

Aerosol release, distribution, and prevention during aerosol therapy: a simulated model for infection control
por: Mac Giolla Eain, Marc, et al.
Publicado: (2021)

Cellular Therapy for the Treatment of Paediatric Respiratory Disease
por: Brennan, Laura C., et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_o1lks3jivuhng7btqfjq0chje9